Atsena Therapeutics Receives Orphan Drug Designation From the FDA for Novel Gene Therapy To Treat Genetic Eye Disease LCA1
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its investigational gene therapy product for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina.
Clearlake Capital and Siris-Backed Constant Contact Agrees To Acquire SharpSpring
Constant Contact, an established leader in online marketing, backed by Clearlake Capital Group, L.P. and Siris Capital, announced it has signed a definitive agreement to acquire UF startup SharpSpring, Inc., a leading cloud-based sales and marketing automation platform, in an all-cash transaction valued at approximately $240 million including outstanding indebtedness.
Revolutionizing the Science of Nerve Repair and Regeneration
Peripheral nerve damage is estimated to affect more than 20 million people in the United States, causing symptoms that range from mild discomfort to severe disability. Damage is often undiagnosed or untreated, and the current standard of care procedures can be associated with limitations that impact the quality of life. UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair, aims to address these issues and provide more efficient treatment options to patients.
Glint Pharmaceuticals Begins Clinical Trials to Treat Corneal Abrasions and Infections
UF startup Glint Pharmaceuticals, an ophthalmic pharmaceutical company that delivers medicated contact lenses to treat eye diseases, announces the start of a phase I safety study to treat corneal infections and superficial injuries.
Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Kenji Fujita, MD, to the newly created position of Chief Medical Officer.
Inspira Awarded $1.98M NIH Grant for Diabetes Therapy
Inspira Therapeutics was awarded a $1.98 million NIH grant to develop its polymeric biomaterial-based tolerogenic treatment for type 1 diabetes.
Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer.
entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients
UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC's subsidiary, Jefferies Funding LLC (Jefferies).
Gene Therapy Manufacturer Expands Its Footprint in Alachua County
AGTC, a UF startup and UF Innovate | Sid Martin Biotech alum, is determined to change the rare diseases narrative.
2021 Cade Prize for Innovation Accepting Entries
The 2021 Cade Prize for Innovation is accepting entries from inventors and entrepreneurs in Alabama, Georgia and Florida from June 1 - August 2, 2021.
